# Shattuck Labs, Inc.: overview STTK · Nasdaq · CIK 1680367 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sttk.md) · [Financials](/companies/sttk/financials.md) · [Filings](/companies/sttk/filings.md) · [Insiders](/companies/sttk/insiders.md) Latest reported revenue: [$0](/filings/0001628280-26-055483.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-055483). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.0](/filings/0001680367-25-000057.md) | [0.0 d](/filings/0001628280-26-014989.md) | [0.0](/filings/0001628280-26-031661.md) | [0.0](/filings/0001628280-26-055483.md) | [1.0](/filings/0001680367-25-000057.md) | [0.0 d](/filings/0001628280-26-014989.md) | [0.0](/filings/0001628280-26-031661.md) | [0.0](/filings/0001628280-26-055483.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(597.9%)](/filings/0001680367-25-000057.md) | not reported | not reported | not reported | [(1071.6%)](/filings/0001680367-25-000057.md) | not reported | not reported | not reported | | Net margin | % | [(556.4%)](/filings/0001680367-25-000057.md) | not reported | not reported | not reported | [(1005.6%)](/filings/0001680367-25-000057.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.33)](/filings/0001680367-25-000057.md) | not reported | [(0.27)](/filings/0001628280-26-031661.md) | [(0.24)](/filings/0001628280-26-055483.md) | [(0.14)](/filings/0001680367-25-000057.md) | not reported | [(0.13)](/filings/0001628280-26-031661.md) | [(0.12)](/filings/0001628280-26-055483.md) | | Free cash flow | $m | [(16.1) d](/filings/0001680367-25-000057.md) | [(17.4) d](/filings/0001628280-26-014989.md) | not reported | not reported | [(9.0) d](/filings/0001680367-25-000057.md) | [(8.5) d](/filings/0001628280-26-014989.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [30.0](/filings/0001680367-23-000019.md) | [0.7](/filings/0001680367-24-000014.md) | [1.7](/filings/0001680367-25-000012.md) | [5.7](/filings/0001628280-26-014989.md) | [1.0](/filings/0001628280-26-014989.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(150.8%)](/filings/0001680367-23-000019.md) | [(15848.0%)](/filings/0001680367-24-000014.md) | [(5549.6%)](/filings/0001680367-25-000012.md) | [(1408.3%)](/filings/0001628280-26-014989.md) | [(5150.8%)](/filings/0001628280-26-014989.md) | | Net margin | % | [(149.8%)](/filings/0001680367-23-000019.md) | [(15635.7%)](/filings/0001680367-24-000014.md) | [(5268.4%)](/filings/0001680367-25-000012.md) | [(1318.1%)](/filings/0001628280-26-014989.md) | [(4880.9%)](/filings/0001628280-26-014989.md) | | Diluted EPS | $ per share | [(1.07)](/filings/0001680367-23-000019.md) | [(2.41)](/filings/0001680367-24-000014.md) | [(2.05)](/filings/0001680367-25-000012.md) | [(1.49)](/filings/0001628280-26-014989.md) | [(0.70)](/filings/0001628280-26-014989.md) | | Free cash flow | $m | [(65.0)](/filings/0001680367-23-000019.md) | [(106)](/filings/0001680367-24-000014.md) | [(81.6)](/filings/0001680367-25-000012.md) | [(60.6)](/filings/0001628280-26-014989.md) | [(40.0)](/filings/0001628280-26-014989.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sttk/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $56.4m | 8,122,179 | | Added +3,477,222 | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $47.8m | 6,892,033 | | Added +1,352,309 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $43.8m | 6,306,127 | | Unchanged | | [Prosight Management, LP](/funds/1617201.md) | 2026-06-30 | $41.3m | 5,957,877 | | Added +953,438 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $27.3m | 3,935,810 | | Added +3,425,004 | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $26.0m | 3,750,000 | | New +3,750,000 | | [NEXTBio Capital Management LP](/funds/2038158.md) | 2026-06-30 | $25.9m | 3,727,348 | | Added +577,441 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $25.7m | 3,706,734 | | New +3,706,734 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.3m | 3,207,865 | | Added +930,689 | | [PINNACLE ASSOCIATES LTD](/funds/743127.md) | 2026-06-30 | $13.0m | 1,871,442 | | Added +503,219 | ## Recent filings [All 405 filings](/companies/sttk/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 06:59 ET | [8-K](/filings/0001628280-26-055484.md) | 2.02 Results of operations | 0001628280-26-055484 | | 2026-08-11 | 06:57 ET | [10-Q](/filings/0001628280-26-055483.md) | Quarterly report, period 2026-06-30 | 0001628280-26-055483 | | 2026-07-17 | 21:30 ET | [SCHEDULE 13D/A](/filings/0001104659-26-084768.md) | Ownership report, active investor, amended | 0001104659-26-084768 | | 2026-06-15 | 18:10 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000624.md) | Ownership report, active investor, amended | 0000947871-26-000624 | | 2026-06-11 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-073086.md) | Ownership report, active investor, amended | 0001104659-26-073086 | | 2026-06-11 | 08:25 ET | [8-K](/filings/0001193125-26-266745.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-266745 | | 2026-06-09 | 16:28 ET | [8-K](/filings/0001193125-26-263831.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-263831 | | 2026-06-02 | 17:00 ET | [8-K](/filings/0001193125-26-253784.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-253784 | | 2026-05-07 | 06:54 ET | [10-Q](/filings/0001628280-26-031661.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031661 | | 2026-05-07 | 06:34 ET | [8-K](/filings/0001628280-26-031643.md) | 2.02 Results of operations | 0001628280-26-031643 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-014989.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ff6bae9e-b13b-4fcd-8573-63da728edccc) ## About the filer - CIK: 1680367 - Tickers: STTK - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.